Authorization

Seelos Therapeutics Gets European Orphan Drug Designation For SLS-005 In Sanfilippo Syndrome

(RTTNews) - Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, Tuesday said it has been granted Orphan Drug Designation for SLS-005 in mucopolysaccharidosis type III, Sanfilippo syndrome, from the European Medicines Agency.

To date, SLS-005 has been granted Orphan Drug Designation in the US and Europe for Sanfilippo syndrome, Spinocerebellar Ataxia Type 3 and Oculopharyngeal Muscular Dystrophy as well as Fast Track designation for OPMD.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2021    »
ПнВтСрЧтПтСбВс
 123
45678910
11121314151617
18192021222324
25262728293031